Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
A PHASE2 clinical study on Overweight or Obesity, this trial is completed. The trial is conducted by Fujian Shengdi Pharmaceutical Co., Ltd. and has accumulated 8 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
May 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Sep 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fujian Shengdi Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Changchun, China , Chengdu, China , Chongqing, China , Guangzhou, China , Haikou, China , Hangzhou, China , Harbin, China , Hefei, China and 14 more locations